Skip to main content
OpenTrials
Recruiting

NCT Number: NCT00291096

High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer

The overall goal of this project is to develop an integrative system of breast cancer risk assessment based on epidemiologic and biologic risk variables, as well as to develop or refine risk biomarkers which may be useful in predicting and monitoring response to prevention interventions.

Recruiting

Interested in participating?

Request Info

Key information

Age range

30 year–65 year

Sex eligibility

Female

Study type

Observational

Primary location

University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

Location status: Recruiting

Location contact

Bruce Kimler, PhD

PRINCIPAL_INVESTIGATOR

Carol J Fabian, MD

PRINCIPAL_INVESTIGATOR

About this study

  • To correlate established risk biomarkers such as cytomorphology obtained from random periareolar fine needle aspiration ( RPFNA), mammographic breast density, serum bioavailable estradiol and IGF-1/IGFBP-3 with each other and with 5-10 year Gail risk estimates. Where available, and with appropriate safe guards to maintain status for breast cancer susceptibility genes may be included.
  • To determine the relative predictive value of established risk biomarkers for the development of DCIS and/or invasive cancer.
  • To evaluate potential new breast tissue-based biomarkers including Ki-67, PCNA, ER, COX-2, aromatase, methylation of key tumor suppressor genes (i.e., RAR, p16, etc), proteomic patterns in RPFNA and nipple aspirate fluid (NAF), as well as NAF hormone levels, and correlate them with other risk biomarkers listed in 1.
  • To determine the prevalence of polymorphisms of a panel of genes important in hormone and xenobiotic metabolism as well as DNA repair and correlate these polymorphisms with established risk biomarkers listed in 1, as well as with development of DCIS and invasive cancer.
  • To maintain contact with this initially identified cohort of high risk women, acquire demographic data, biologic specimens and data and follow them prospectively for the development.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • women with at least 2 times the normal risk of developing breast cancer
  • between the ages of 30-65 (or within 10 years of youngest age at diagnosis in first degree relative)
  • greater than six months from ingestion of antihormonal therapy
  • greater than 1 year from pregnancy, lactation, or chemotherapy
  • willing to have a mammogram within six months prior to RPFNA
  • willing to discontinue NSAIDS or herbal supplements
  • willing to have blood drawn

Exclusion criteria

  • no metastatic malignancy of any kind
  • no breast implants or tram flap reconstructions
  • no radiation to both breasts
  • no women who have a current mammogram or clinical breast exam suspicious for cancer

Treatment and study plan

Primary outcomes

  1. Prediction of risk for developing breast cancer

    Time frame: ongoing

    development of algorithm for predicting risk for developing breast cancer based on random sampling of benign breast tissue.

Study contacts

Contact information is provided by the study sponsor or research team.

Bruce Kimler, Ph.D.

CONTACT

[email protected]

913-588-4523

Sponsors and collaborators

Lead sponsor

Carol Fabian, MD

Other

Registry information

Important dates

Study start
1989
Primary completion
2027
Study completion
2027
First posted
Feb 13, 2006
Registry last updated
Oct 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.